Clinical Trials Logo

Biliary Tract Neoplasms clinical trials

View clinical trials related to Biliary Tract Neoplasms.

Filter by:

NCT ID: NCT06239194 Recruiting - Breast Cancer Clinical Trials

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Start date: June 12, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

NCT ID: NCT06230471 Recruiting - Clinical trials for Biliary Tract Neoplasms Immunotherapy

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Start date: January 9, 2024
Phase: Phase 2
Study type: Interventional

Explore the impact of the first-line application of Pembrolizumab with or without Lenvatinib or chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers

NCT ID: NCT06222619 Completed - Clinical trials for Biliary Tract Cancer

Effect of PVE on Surgical Outcomes and Long-term Survival in Perihilar Cholangiocarcinoma

Start date: January 30, 2020
Phase:
Study type: Observational

Portal vein embolization is often recommended to reduce the risk of postoperative liver failure and mortality. In this retrospective cohort study, researchers investigated the effect of portal vein embolization in patients with resectable perihilar cholangiocarcinoma bismuth type III and IV.

NCT ID: NCT06202131 Recruiting - Colon Cancer Clinical Trials

Prospective Single-center Study About the Use of ctDNA in the Management of Patients With Tumors of the Gastrointestinal Tract

ctDNA-GI
Start date: November 1, 2023
Phase:
Study type: Observational

This study will evaluate the use of ctDNA in the clinical management of patients with tumors of the gastrointestinal tract.

NCT ID: NCT06178445 Recruiting - Clinical trials for Biliary Tract Cancer

Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer

TRAP-BTC
Start date: April 17, 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity triplet regimen consisting of a combination of chemotherapy (gemcitabine/cisplatin) + trastuzumab + pembrolizumab as first-line treatment for cholangiocarcinoma and gallbladder cancer patients. Patients suffering from previously untreated HER2 (human epidermal growth factor receptor 2) positive, unresectable cholangiocarcinoma and gallbladder cancer will be included in the study and are scheduled to receive triplet regimen consisting of a combination of pembrolizumab, trastuzumab and gemcitabine/cisplatin (GemCis).

NCT ID: NCT06171321 Not yet recruiting - Clinical trials for Biliary Tract Cancer

Circulating Tumor DNA Guided Adjuvant Chemotherapy for Biliary Tract Carcinoma

Start date: December 2023
Phase: N/A
Study type: Interventional

In recent years, circulating tumor DNA (ctDNA)had achieved encouraging results in monitoring recurrence and metastasis after surgery, and has potential clinical application value. The presence of ctDNA after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence. The benefit of adjuvant chemotherapy for ctDNA-positive patients is not well understood.

NCT ID: NCT06139042 Recruiting - Pancreatic Cancer Clinical Trials

Early-stage Detection of LIver, Biliary tRAct and pancReatic Cancers

Start date: November 1, 2023
Phase:
Study type: Observational

LIBRARY is a prospective, multi-center, observational study aimed at detecting early liver, biliary tract, and pancreatic cancers by combining assays of cell-free DNA (cfDNA) methylation, serum protein, and microRNA.

NCT ID: NCT06134193 Not yet recruiting - Carcinoma Clinical Trials

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Start date: November 2023
Phase: Phase 2
Study type: Interventional

This is a single-arm, exploratory study to evaluate the efficacy and safety of HAIC in combination with surufatinib and tislelizumab in the first line treatment of patients with unresectable or metastatic biliary tract cancer

NCT ID: NCT06109779 Recruiting - Clinical trials for Biliary Tract Cancer

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Start date: December 4, 2023
Phase: Phase 3
Study type: Interventional

A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.

NCT ID: NCT06084689 Not yet recruiting - Colorectal Cancer Clinical Trials

Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

EMPIRE
Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

Phase II, multicenter, open-label, multi-cohort proof-of-concept study designed to evaluate the safety and efficacy of Ezabenlimab combined with BI 907828 in patients with unresectable, locally advanced or metastatic solid tumors.